Introduction and hypothesis Botulinum toxin has become a widely adopted treatment for patients with recalcitrant overactive bladder (OAB) symptoms. Some recommend clean intermittent self-catheterisation (CISC) if a postvoid residual (PVR) >200 ml posttreatment, but there is no evidence for this recommendation. The aim of this study was to identify whether abstinence from CISC as a routine strategy for patients with a PVR following intradetrusor botulinum toxin injections is associated with any measurable adversity. Methods This was a cohort observation study. Patients with lower urinary tract symptoms (LUTS) attending a medical urology centre were observed before and after botulinum toxin treatment. Intradetrusal botulinum toxin injections were administered in the day-treatment centre at a medical urology centre in London, UK. Patients were reviewed at follow-up consultations to measure PVR. Results Of the 240 patients studied, 215 were women and 25 were men, of whom, 196 (82%) received botulinum toxin injections and were not managed with CISC; 18% were using CISC prior to injections and continued. None of the 196 patients developed acute retention or significant voiding symptoms. Conclusions Our study indicates that routine administration of CISC based on an arbitrary PVR volume is unlikely to confer benefit. In order to avoid patients being deterred from botulinum treatment, we recommend that CISC be reserved for those who have troublesome voiding symptoms as well as a raised PVR. It is unlikely that CISC, initiated on the basis of an arbitrary PVR volume, would benefit the patient.
Introduction
Intradetrusal injection of botulinum toxin has become a widely adopted practice for treating patients with recalcitrant overactive bladder (OAB) symptoms. There is good evidence of efficacy, with improved quality of life (QoL) [1] . The literature recommends that postinjection, patients with a postvoid residual (PVR) urine ≥ 150 ml or ≥ 200 ml, should be started on clean intermittent self-catheterisation (CISC) [2] , but this discourages patients from undergoing treatment [3, 4] and some refuse repeat injections because they disliked or could not perform CISC [2] . Given this barrier, it is surprising that there is no published evidence to justify advising CISC on the indication of a PVR threshold. Why, then, are physicians recommending invasive treatment in the absence of justifiable evidence?
Complete urine retention and unpleasant voiding symptoms relieved by CISC would seem strong indications for its use. A number of consensus statements define PVR volumes beyond which CISC should be initiated, but they do not reference evidence of validation [5] . Some might argue that CISC be used to protect against hydronephrosis, as is the case after spinal cord injury, but botulinum toxin reduces detrusor contractility [6] , obviating the risk unless complete retention occurs. Thus, there is legitimate doubt about whether CISC confers benefit, or avoids harm, to those who have a PVR over a predetermined threshold. However, it is well known that that it causes substantial patient inconvenience [7] .
There have been a number of randomised controlled trials of botulinum toxin injections for overactive bladder or bladder hyperreflexia. In every case, there has been an emphasis on measuring voiding function postinjection by assessing PVR, and in those trials, CISC was initiated for PVR ≥ 200 ml-and in one case, ≥ 150 ml [3, [8] [9] [10] [11] [12] . In none of those studies was a justification or explanation offered for determining that threshold for initiating CISC.
We observed a number of patients who declined CISC despite an increased PVR after botulinum toxin injection, and they came to no harm. Given the absence of evidence for its benefit, we ceased recommending CISC based on an arbitrary PVR and reserved the method for patients who developed acute retention or symptoms of retention reversed by CISC and those already using CISC prior to botulinum toxin treatment.
If clinicians wish to recommend CISC based on a PVR, then data from a randomised controlled trial (RCT) should justify it. Prior to embarking on an RCT, it is necessary to know whether an effect is likely to be detected, and if so, what the likely size will be. No such data exists; so, before considering an RCT, the first task must be an observational study to determine a priori whether there is a problem in the first place that requires CISC as a remedy. We ascertained whether patients experience any measurable harm following botulinum toxin injection when not using CISC, regardless of their PVR. The aim of the study was to identify whether not using CISC as a treatment following intradetrusor botulinum toxin injections in patients with PVR was associated with any measureable adversity. 
Materials and methods
The study was approved by Noclor Research London -St Pancras Reference 168107. This was a cohort observation that began in June 2011 lasted until January 2013. Patients with lower urinary tract symptoms (LUTS) attending a medical urology centre in London were observed before and after botulinum toxin treatment. Male and female patients diagnosed with refractory overactive bladder (OAB), unresponsive to antimuscarinic agents, with bladder retraining and were offered botulinum toxin injections as treatment were observed. OAB symptoms were diagnosed using a validated hybrid International Consultation on Incontinence Questionnaire (ICIQ) and Female Lower Urinary Tract Symptoms (FLUTS) questionnaire, with sections of the questionnaire focusing on urinary frequency and urgency symptoms. Patients were given an information sheet about the botulinum toxin treatment, were provided with a counselling session and an opportunity to ask questions and address concerns, were informed about the risks associated with the intervention and given a choice over local or general anaesthetic. A written informed consent was obtained. Patients who consented were later put on the surgical list for botulinum toxin injections.
Intradetrusal botulinum toxin injections were administered in the day-treatment centre at a north London hospital by two different consultant gynaecologists on various days. Patients were administered Allergan (Botox A) 200 IU, injected in 20× 1-ml aliquots, in an array pattern and sparing the trigone; 200 IU was the standard dose according to local clinical guidelines and authorised by the chief pharmacist and medicines management committee at the hospital trust. A dose <200 IU had been audited as ineffective in patients requiring frequent subsequent injections. The injections were placed in the detrusor muscle rather than just under the urothelium and mainly in the base and sidewalls of the bladder (avoiding the trigone), as this is where the bladder afferents are clustered. Two weeks later patients were reviewed, and during the interim, they continued with prior antimuscarinic therapy. They had the option of earlier contact with the medical urology centre if necessary. At follow-up, consultation patients were asked about specific side effects, voiding dysfunction and symptoms of infection. The ICIQ-FLUTS questionnaire, which focuses on urinary frequency, urgency symptoms, stress symptoms, voiding symptoms, pain symptoms and QoL was used to analyse symptoms. The symptom set is described in Fig. 1 , which demonstrates symptom distribution. Patients provided a midstream urine specimen for dipstick analysis, light microscopy for pyuria and routine culture; a bladder scan was conducted to measure PVR. This assessment protocol was carried out during each follow-up consultation, and patients were treated for a urinary tract infection (UTI) if it was diagnosed. Patients with a PVR ≥ 150 ml had a blood sample obtained to measure creatinine and monitor kidney function. A creatinine between 70 and 120 µM/L was accepted according to local clinical guidelines; patients not within those parameters were required to have a renal tract scan to detect the probability of hydronephrosis. Patients unable to void or used CISC preoperatively were managed with CISC. The technique was not advocated in other cases unless a patient described clear, troublesome voiding symptoms that were relieved by removing residual urine. In such cases, CISC was taught in a private consultation room. Patients were given an information sheet on how to perform CISC, verbal instructions on the principles and technique of catheter insertion and informed about infection control. They were routinely followed up in the outpatient department 2 weeks after the first botulinum treatment, followed by 4, 6, and 8 weeks. The same assessments and checks were repeated at each visit. Patients had the opportunity to attend the department earlier if they were concerned or experienced LUTS. The sample size was calculated using G*Power© version 3.1.9.2 using the Wilcoxon and Mann-Whitney tests. The smallest clinically significant effect size that would justify changing practice was estimated as three symptoms from a score that measured 39 symptoms, where zero represented no symptoms. The estimate drew on data obtained from an observational study of patients treated for OAB [13] . This gave a Cohen's d d ¼ 
Results
We assessed 240 patients: 215 women and 25 men, with a mean age of 57.6 [standard deviation (SD) 14.7] and 49.1 (SD 14.4) years, respectively, with the difference being insignificant. The distribution of LUTS symptoms measured after botulinum treatment and their overlap are shown in the Venn diagram in Fig. 1 . Of the 240 patients, 43 (18%) used CISC prior to treatment and continued it afterwards. Twelve patients (5%) had medical histories of autonomic neuropathy, spina bifida, cerebrovascular disease or multiple sclerosis; 31 (13%) who were using CISC prior to treatment sustained voiding symptoms after botulinum toxin injections and reported them as troublesome and relieved by continued use of CISC. The 196 patients (82%) not managed with CISC were reviewed serially. Their residual urine gradually subsided over time and, as no voiding symptoms or urinary retention developed after injection, there was no need for management with CISC. There were many similarities in baseline data between patients in the CISC and non-CISC groups (Table 1) . Mean symptom duration for both groups was 7.35 years (SD 3.8), and numbers were similar for 24-h incontinence episodes (mean = 2.8; SD 2), pain symptoms (mean = 0.57; SD 0.976) and urgency symptoms (mean = 5.5; SD 3). The number of voiding symptoms was higher in the non-CISC group (average = 7.3; SD 4.8) compared with the CISC group (average = 7.0; SD 5.5). The CISC group appeared to have more stress incontinence symptoms (average = 3, SD 2.6. median = 4.0) compared with the non-CISC group (average = 0.75, SD 1.0, median = 0.5), but this was not statistically significant (MannWhitney U = 1986; p = 0.74). The comparison is shown in Tables 2 and 3 . After botulinum toxin injection, there was no significant difference in PVR between patients who did and did not use CISC (mean = 2.2 ml, SD 8.8, median = 0 and mean = 20, SD 55, median = 0, respectively; Mann-Whitney U = 1222, p = 0.29). Combined PVR volume in patients using CISC was 111 ml (95% CI = 68-1544; max = 1400 ml, range = 20 ml); Fig. 2 ). For those not using CISC, combined PVR volume was 82 ml (95% CI = 73-90 ml; max = 1100, range = 10 ml), and again, the difference was not statistically significant (MannWhitney U = 70,786, p = 0.77). Those not using CISC showed a wide variance (Fig. 3) . Figure 4 plots symptoms scores of the 240 patients within the observation and the average total. The ICIQ-FLUTS questionnaire was used as an assessment tool at each follow-up visit. There was a significant decrease in symptoms at the first visit visit after injection, which was maintained at the second visit; symptoms returned at the third and fourth visits. There were no between-group differences in urgency, selfassessment of treatment response, frequency, incontinence, voiding, or pain. There were no differences in pyuria or positive urine culture and no evidence of differences in renal biochemistry at any stage during follow-up. At the third and fourth follow-up, symptoms of urgency became dominant. PVR with each visit (Fig. 3) , in contrast to those using CISC (Fig. 2) . Patients not using CISC, including those with a PVR ≥ 150 ml , failed to demonstrate any symptoms, sign, or pathology that would necessitate CISC.
Discussion
Current clinical practice advocates the use of CISC based on a PVR of ≥150 ml. This is an arbitrary criterion that is not based on evidence. We use CISC, but only in patients with symptoms that could be demonstrably relieved by CISC. Thus, a number of our patients lived with significant PVR volumes, well >150 ml, following botulinum toxin injection. They appeared to experience no adverse effects, such a hydronephrosis or urinary retention. This is important, because many are denied the option of botulinum injection due to concerns about such conditions following injections. Our data imply that such fears may be exaggerated. This study has limitations: Investigators were not blinded; QoL was not measured, and this was not a randomised controlled trial. To some extent, the lack of blinding was not an issue, as we used and objective measure (PVR), which dropped in the weeks following injection. Such data make an RCT extremely difficult to justify because we detected no significant adversity in patients who did not use CISC. Thus, we are unable to propose a plausible outcome measure or offer a variable suitable for a sample-size estimate. If observational data cannot detect a significant outcome, an RCT would be less likely to do so.
The study was motivated by patient preference following experiences with patients refusing CISC after a significant PVR was detected with no adverse effects. CISC can be avoided by ensuring that patients are frequently monitored and assessed for retention symptoms posttreatment. Many patients are alarmed at the prospect of CISC and state reluctance to comply, with the result that they do not receive botulinum toxin treatment. This study has led us to using a different approach to consent. We explain that we shall do our utmost to avoid using CISC, despite some degree of retention, and will use it for limited periods only if a symptomatic retention occurs. This seems a more feasible option for our patients, and more patients therefore consent to treatment. Introducing CISC should be based on individual symptom assessments following treatment. A patient reporting troublesome voiding symptoms, such as hesitancy, reduced stream, intermittent stream and straining to void should be considered for CISC; however, this study indicates that patients without such symptoms are unlikely to benefit from the procedure.
Compliance with ethical standards
Finacial disclaimer/Conflict of interest None.
